MedTrace Logo

A Prospective, Randomized, Investigator-blinded, Parallel, Multi-center, Phase 3 Trial

NCT05670470 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2023-03-01

No results posted yet for this study

Summary

This is a prospective randomized study compared with active control arm.

Conditions

  • Bowel Preparation

Interventions

DRUG

CTP0303

Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.

DRUG

Orafang Tab

Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.

Sponsors & Collaborators

  • Taejoon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jae Myung Cha, MD, PhD · Kyung Hee University Hospital at Gangdong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-21
Primary Completion
2023-01-15
Completion
2023-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05670470 on ClinicalTrials.gov